N-(piperidin-2-ylmethyl)methanesulfonamide | 1016509-49-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(piperidin-2-ylmethyl)methanesulfonamide
• CAS: 1016509-49-1
• 化学式: C₇H₁₆N₂O₂S
• 分子量: 192.28
• InChiKey: RLDATXAEQVWQGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] INHIBITORS OF HEPATITIS C VIRUS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：PRESIDIO PHARMACEUTICALS INC

  公开号：WO2012058125A1

  公开（公告）日：2012-05-03

  A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV.

  揭示了一类抑制丙型肝炎病毒（HCV）的化合物，以及含有该化合物的组合物和使用该组合物治疗感染HCV的个体的方法。
• Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
  申请人：SOUTHERN RESEARCH INSTITUTE

  公开号：US11524010B2

  公开（公告）日：2022-12-13

  In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，公开了抑制TXNIP表达和/或降低肝糖生成的化合物和组合物，以及识别、制造和使用这些化合物和组合物的方法。所公开的化合物和组合物可用于治疗与 TXNIP 升高和/或胰高血糖素水平升高相关的疾病，例如糖尿病及相关疾病。此外，还提供了治疗高脂血症或脂肪肝的方法，这些疾病可选地与 TXNIP 和/或胰高血糖素水平升高有关。本摘要旨在作为一种扫描工具，用于特定技术领域的搜索，并非对本发明的限制。
• SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS
  申请人：SOUTHERN RESEARCH INSTITUTE

  公开号：US20200038402A1

  公开（公告）日：2020-02-06

  In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels.